MedTrace Logo

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

NCT04512053 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2022-02-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.

Conditions

  • Stress Urinary Incontinence

Interventions

DRUG

TAS-303 18 mg/day

Oral administration for 12 weeks, once daily

DRUG

Placebo

Oral administration for 12 weeks, once daily

Sponsors & Collaborators

  • Taiho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taiho Pharmaceutical Co., Ltd. · Taiho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-04
Primary Completion
2021-12-22
Completion
2021-12-22

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512053 on ClinicalTrials.gov